Testing speech analysis to predict response to psychiatric treatments
Tests whether speech patterns predict response to TMS or Spravato in adults.
Key facts
- Who runs it
- Psyrin Inc.
- Where
- New York and Sunnyvale, United StatesSee the 2 sites
- Trial code
- Registry title
- Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions
- Status
- Enrolling by invitation
- People taking part
- 200 people, planned
- Started
- 18 Feb 2025
- Planned end
- Mar 2026
- Type of study
- Observational, 2 groups
- Record updated
- 18 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult outpatients with depression, PTSD or bipolar disorder who are about to start TMS or Spravato treatment. They will record their speech so researchers can see if it predicts treatment response.
- Age
- 18 to 68 years
- Sex
- Men and women
- Disease stage
- Diagnosis of MDD, PTSD or BD; scheduled to receive TMS or Spravato (esketamine) treatment; outpatient.
- Earlier treatment
- Must be stable on medication for at least 2 months, with no changes expected during the study. If in psychotherapy, must have been in stable treatment for at least 3 months.
Main reasons for not taking part
- Used any investigational drug within 4 weeks of the baseline visit
- Intoxicated during speech assessments
- Cognitive impairment that would interfere with the study
- Not fluent in English
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Outpatient status
- Men and women aged 18-68 years
- Capable and willing to provide informed consent
- Able to adhere to the treatment schedule
- Stable on medication for at least 2 months with no anticipated changes during the study period
- Diagnosis of MDD, PTSD, or BD
- Eligible for and scheduled to receive TMS or Spravato (esketamine) treatment to alleviate symptoms of MDD, PTSD, GAD, OCD or BD
- Fluent in English
- Access to a stable internet connection and an electronic device with a microphone for voice recording
Who cannot take part
- Use of any investigational drug within four weeks of the baseline visit
- If participating in psychotherapy, the patient must have been in stable treatment for at least three months before study entry, with no anticipated changes in the frequency of therapeutic sessions or therapeutic focus during the TMS or Spravato treatment
- Cognitive impairment that would interfere with study participation or data quality
- Intoxication during speech assessments
- Lack of fluency in English
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 68 years old?
Where in United States
- Fermata HealthNew York, United StatesEnrolling by invitation
- Acacia ClinicsSunnyvale, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This is a research study looking at whether the way people speak can help predict how well they'll respond to certain mental health treatments.
Read full original descriptionShow less
The Main Goal:
The researchers want to see if computer analysis of a person's speech patterns can predict whether they'll respond well to two specific treatments: TMS (Transcranial Magnetic Stimulation) and Spravato (a nasal spray medication). They're focusing on people with depression, bipolar disorder, OCD, anxiety, and PTSD.
How It Works:
200 people with these conditions will participate in the study.Participants will record themselves speaking for about 12 minutes, responding to six different prompts.They'll do these recordings before treatment starts, daily during treatment, right after treatment ends, and again four weeks later. Doctors will track how well people are doing using various questionnaires and rating scales The researchers will look for connections between speech patterns and treatment success. The study will last 12 months.
What Makes Someone a "Treatment Success":
The study considers treatment successful if a person's symptoms improve significantly (specifically, a 2-point or greater reduction on a clinical rating scale (called Clinical Global Impression) and stays improved during the follow-up period (4-weeks).
Why This Matters:
If successful, this research could lead to a simple, non-invasive way to help doctors predict which treatments might work best for different patients. This could help people get the most effective treatment more quickly and help healthcare providers use their resources more efficiently.
Safety Consideration The researchers will also check whether doing the speech assessments causes any distress to participants, making sure the evaluation process itself is safe and comfortable.
The 2 groups in the trial
- Participants prescribed esketamine
Participants who in their normal course of treatment are prescribed and are administered Spravato (esketamine) within 4 weeks of baseline assessment.
- Participants prescribed TMS
Participants who in their normal course of treatment are prescribed and are administered repetitive transcranial magnetic stimulation within 4 weeks of baseline assessment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Observational, Prospective Study to Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions
- Plain-language title
- Testing speech analysis to predict response to psychiatric treatmentsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06823024, who can take part
- Record updated
- 18 March 2025